Old Simcere (China) JV Returned To JV Partner In Q2 2015: Merck’s Just Filed SEC Form 10-Q

This is a rather smallish item, but as I review the SEC Form 10-Q just filed this evening, I thought I’d note it (so I don’t forget it!) — since we’ve covered the Simcere JV for five years. [Previous backgrounder here. Earlier stuff here.]

The JV will no longer be included in Kenilworth’s consolidated results — and a tiny charge was taken on the divestiture, per page 48 of the SEC filing:

. . . .In March 2015, Merck and Simcere Pharmaceutical Group (“Simcere”) executed a restructuring agreement in which Merck agreed to transfer its 51% ownership interest in the Simcere MSD Shanghai Pharmaceutical Co., Ltd. joint venture to Simcere. As a result, Merck deconsolidated the joint venture and recorded a net loss of $7 million in Other (income) expense, net in the first six months of 2015. . . .

Onward — and a torch still burns, brightly. . .


There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: